Source comparison
CJC-1295 MK-677 Stack Protocol: Research Compound Comparison
The CJC-1295 MK-677 stack protocol is one of multiple growth hormone secretagogue approaches available for research. The table below compares mechanism, half-life, administration route, and typical IGF-1 response across the most common alternatives. CJC-1295 +
This comparison does not assign a generated winner or score.
- The CJC-1295 MK-677 stack protocol is one of multiple growth hormone secretagogue approaches available for research. The table below compares mechanism, half-life, administration route, and typical IGF-1 response across the most common alternatives.
- CJC-1295 + MK-677 Stack
- Dual-pathway: GHRH receptor agonist (pituitary) + ghrelin receptor agonist (hypothalamus)
- CJC: 6–8 days; MK-677: 24 hours
- CJC: subcutaneous injection; MK-677: oral
- 50–80% above baseline sustained
- CJC: weekly; MK-677: daily
- Best synergy for sustained IGF-1 elevation without daily injections; requires consistent MK-677 compliance
- Ipamorelin + CJC-1295 (No DAC)
- Dual-injection: GHRP + GHRH analog without DAC modification
- Ipamorelin: 2 hours; CJC No DAC: 30 minutes
- Both subcutaneous injection
- 40–60% elevation during pulse windows
- 2–3× daily for both compounds
- Higher peak GH response but requires multiple daily injections; more suitable for acute pulse studies than chronic elevation
- MK-677 Monotherapy
- Ghrelin receptor agonist only
- 24 hours
- Oral
- 30–50% above baseline
- Daily
- Simplest protocol; lower peak response than dual-mechanism stacks; oral administration reduces compliance barriers
- Tesamorelin + Ipamorelin
- GHRH analog (FDA-approved for lipodystrophy) + GHRP
- Tesamorelin: 26–38 minutes; Ipamorelin: 2 hours
- 35–55% elevation during dosing window
- Daily for both
- Tesamorelin is FDA-approved (different regulatory pathway); short half-life limits sustained elevation
- IGF-1 LR3 Direct Administration
- Bypasses GH entirely. Direct IGF-1 receptor agonism
- 20–30 hours
- Subcutaneous injection
- Variable (exogenous IGF-1, not endogenous production)
- Daily or every other day
- Removes endogenous GH feedback loops entirely; useful for isolating IGF-1 effects independent of GH; higher regulatory scrutiny
- The CJC-1295 MK-677 stack protocol sits in the middle ground between convenience and efficacy. It avoids the compliance burden of multiple daily injections (required for Ipamorelin + CJC No DAC) while producing higher sustained IGF-1 elevation than MK-677 alone. For research teams prioritizing consistent plasma levels across multi-week studies without requiring subjects to perform daily injections, this stack offers the best risk-to-benefit ratio. You can compare related formulations like Ipamorelin and IGF 1 LR3 to see how mechanism variations impact study design requirements.